|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prasugrel#Adult Indications and Dosage]] |
| {{Prasugrel}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications And Usage==
| |
| | |
| ===Acute Coronary Syndrome===
| |
| | |
| Effient® is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with [[percutaneous coronary intervention]] ([[PCI]]) as follows:
| |
| | |
| *Patients with [[unstable angina]] ([[UA]]) or non-ST-elevation [[myocardial infarction]]([[NSTEMI]]).
| |
| *Patients with ST-elevation [[myocardial infarction]](STEMI) when managed with primary or delayed PCI.
| |
| | |
| Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal [[myocardial infarction]]([[MI]]), or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death [see Clinical Studies (14)].
| |
| | |
| It is generally recommended that [[antiplatelet]] therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation. In the clinical trial that established the efficacy of Effient, Effient and the control drug were not administered to [[UA]]/[[NSTEMI]] patients until coronary anatomy was established. For the small fraction of patients that required urgent [[CABG]] after treatment with Effient, the risk of significant bleeding was substantial [see Warnings and Precautions (5.2)]. Because the large majority of patients are managed without [[CABG]], however, treatment can be considered before determining coronary anatomy if need for [[CABG]] is considered unlikely. The advantages of earlier treatment with Effient must then be balanced against the increased rate of bleeding in patients who do need to undergo urgent [[CABG]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6 | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6 | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |